Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA Closes $20.6M Funding Round

NEW YORK — Belgian molecular diagnostics firm OncoDNA said on Friday that it has closed a €19 million ($20.6 million) Series B financing round.

The round was led by Vesalius Biocapital III and Swisscanto Invest by Zürcher Kantonalbank. Other participants included SFPI-FPIM, CPH Bank, Inventures, Sambrinvest, Sofinim, SRIW, and undisclosed existing investors.

OncoDNA, which raised €7.7 million in 2016, said it will use the new funding to support its international growth, accelerate software development, and to expand its workforce.

"We [have] built a worldwide network of more than several thousand oncologists, OncoDNA Founder and CEO Jean-Pol Detiffe said in a statement. "Our next move is to connect molecular laboratories to our advanced data interpretation tools, which we pride ourselves on now being possible thanks to the support of our new investors."

About a year ago, OncoDNA released its OncoNTRK RNA sequencing assay for solid or liquid biopsies analysis of tumors with potential NTRK gene fusions. A few months before that, it updated its next-generation sequencing-based OncoDeep solid tumor analysis tool.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.